Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E20.66 EPS (ttm)5.95 Insider Own0.02% Shs Outstand2.70B Perf Week-2.25%
Market Cap331.77B Forward P/E16.02 EPS next Y7.67 Insider Trans-20.29% Shs Float2.70B Perf Month-2.39%
Income16.51B PEG3.27 EPS next Q1.78 Inst Own67.40% Short Float0.68% Perf Quarter8.60%
Sales72.17B P/S4.60 EPS this Y8.30% Inst Trans-0.11% Short Ratio2.60 Perf Half Y8.43%
Book/sh26.02 P/B4.72 EPS next Y8.01% ROA- Target Price128.71 Perf Year11.44%
Cash/sh- P/C- EPS next 5Y6.32% ROE- 52W Range108.51 - 129.00 Perf YTD7.37%
Dividend3.20 P/FCF- EPS past 5Y11.20% ROI17.00% 52W High-4.74% Beta0.81
Dividend %2.60% Quick Ratio- Sales past 5Y2.00% Gross Margin69.90% 52W Low13.25% ATR1.22
Employees126400 Current Ratio- Sales Q/Q1.60% Oper. Margin27.80% RSI (14)45.13 Volatility0.98% 0.80%
OptionableYes Debt/Eq- EPS Q/Q1.00% Profit Margin22.90% Rel Volume0.77 Prev Close121.76
ShortableYes LT Debt/Eq- EarningsApr 18 BMO Payout53.10% Avg Volume7.05M Price122.89
Recom2.50 SMA20-1.16% SMA50-0.33% SMA2004.18% Volume5,451,444 Change0.93%
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Apr-24-17 05:49PM  3 Top Consumer Staples Stocks to Buy in 2017 Motley Fool
04:59PM  Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today Motley Fool
04:22PM  Were Johnson & Johnson's Earnings Really That Bad? Motley Fool
04:06PM  J&J Snack Foods misses 2Q profit forecasts Associated Press
03:24PM  Top Stocks for Beginners Motley Fool
01:39PM  Johnson & Johnson to Host Pharmaceutical Business Review PR Newswire
01:02PM  J&J, Bayer Accused of Hiding Blood-Thinning Drug's Flaws Bloomberg
11:02AM  EMERGING MARKETS-Brazil real, Mexico peso strengthen on French vote Reuters
10:38AM  JNJ on the Street: What the Analysts Say after the 3Q16 Results Market Realist
10:37AM  J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say Reuters
09:08AM  Understanding JNJs Stock Performance after the 1Q17 Results Market Realist
07:38AM  JNJs Medical Device Segments Key Growth Factors in 1Q17 Market Realist
07:36AM  A Look at Johnson & Johnsons Major Developments in 1Q17 Market Realist
07:13AM  3 Stocks You Can Buy and Hold Forever Motley Fool
05:52AM  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS Zacks
05:26AM  India to expand access to J&J's TB drug this year Reuters
Apr-23-17 06:55PM  Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
01:07PM  11 Most Profitable Companies In The Fortune 500 Insider Monkey
07:13AM  Meet Carbon, Who With Big Backers Google and General Electric Wants to Revolutionize Manufacturing
Apr-22-17 12:08AM  FDA OKs Samsung Bioepiss Biosimilar Version Of J&Js Remicade The Wall Street Journal
12:02AM  Samsung Bioepis wins FDA approval for rheumatoid arthritis drug that competes with Johnson & Johnson CNBC
12:01AM  [$$] A Band-Aid for J&J
Apr-21-17 10:21PM  U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade - company Reuters
06:52PM  U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade -company Reuters
06:52PM  South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade CNBC
05:56PM  Dow 30 Stock Roundup: AmEx, UNH Beat; Goldman, JNJ, Verizon Disappoint Zacks
05:35PM  Behind JNJs Medical Devices Growth Trajectory Market Realist
05:03PM  FDA OKs Samsung Bioepis's Biosimilar Version Of J&J's Remicade The Wall Street Journal
03:56PM  Your Key Highlights from JNJs 1Q17 Results Market Realist
02:41PM  3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings Update Motley Fool
10:36AM  How Johnson & Johnsons Medical Devices Segment Fared in 1Q17 Market Realist
10:36AM  Eli Lillys Estimate for Strattera, Other Neuroscience Products Market Realist
09:57AM  What's in Store for AbbVie (ABBV) this Earnings Season? Zacks
09:06AM  Johnson & Johnsons Consumer Segments 1Q17 Earnings Market Realist
07:49AM  3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson Motley Fool
07:36AM  Johnson & Johnsons Pharmaceuticals Segments 1Q17 Earnings Market Realist
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
07:00AM  Top 10 Dividend Stocks to Buy Before the Next Recession
Apr-20-17 05:05PM  Johnson & Johnsons 1Q17 Segment-by-Segment Performance Market Realist
03:35PM  Johnson & Johnsons 1Q17 Earnings: Changes in Its Growth Rate Market Realist
03:28PM  I Can't Believe Intuitive Surgical, Inc. Just Spent $2 Billion on Stock Buybacks Motley Fool
01:46PM  Johnson & Johnsons 1Q17 Earnings Miss Revenue Estimates Market Realist
01:06PM  This $26 Billion Company Is the Market's Most Overpriced Biotech Stock Motley Fool
08:40AM  Better Buy: Verizon Communications Inc. vs. Johnson & Johnson Motley Fool
08:36AM  4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings Zacks
07:53AM  J&J target Actelion could exit Swiss benchmark SMI index this month Reuters
07:30AM  Today's Research Reports on Stocks to Watch: Johnson & Johnson and United Continental Accesswire
07:14AM  Sanofi says could buy device assets to boost diabetes Reuters
Apr-19-17 04:24PM  Abbott Delivers Street-Crushing Q1 Following St. Jude Buy Investor's Business Daily
04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
03:47PM  Better Buy: Merck & Co. Inc. vs. Johnson & Johnson Motley Fool
12:19PM  Abbott sees Alere as challenging "fixer-upper" after revised deal Reuters
12:17PM  Artificial intelligence could build new drugs faster than any human team Quartz
10:55AM  Lackluster J&J Q1 Pushes Healthcare ETFs Down Zacks
10:09AM  Intuitive Surgical stock rises 6% after first-quarter earnings beat MarketWatch
08:42AM  5 Ways Johnson & Johnson Disappointed Us With Its Q1 Results Motley Fool
08:31AM  Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : April 19, 2017 Capital Cube
08:24AM  Can Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse? Motley Fool
Apr-18-17 11:32PM  [$$] Johnson & Johnson Lifts Forecast on Actelion Tie-Up The Wall Street Journal
11:30PM  Asian stocks slip on UK surprise election, weak earnings Associated Press
11:27PM  Asian stocks slip on UK surprise election, weak earnings Associated Press
07:35PM  Edited Transcript of JNJ earnings conference call or presentation 18-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
07:07PM  Business Highlights Associated Press
05:16PM  What Happened in the Stock Market Today Motley Fool
05:03PM  Stock Market Roundup, April 18: NFLX, JNJ, GS, HOG Slump on Earnings Zacks
04:54PM  Stocks ended the trading session more than 100 points low... CNBC Videos
04:38PM  How major US stock market indexes fared on Tuesday Associated Press
04:37PM  Stock market ends lower as Goldman, Netflix earnings disappoint MarketWatch
04:36PM  JNJ's Valuation? Questionable, Despite Solid Earnings Investopedia
04:25PM  Dow's Johnson & Johnson Sets Up Lackluster Results For Sector Investor's Business Daily
04:15PM  US STOCKS-Goldman Sachs, J&J pull Wall Street lower Reuters
04:01PM  Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs Investor's Business Daily
04:01PM  Goldman Sachs, Johnson & Johnson Sink the DJIA Tuesday 24/7 Wall St.
03:30PM  Stocks Off, Dow Industrials Cut Losses; Will These 3 IPOs Emerge As New Leaders? Investor's Business Daily
03:12PM  Dow slumps as Goldman, Johnson & Johnson weigh Yahoo Finance
03:00PM  Stocks will continue to churn and disappoint investors: trader Yahoo Finance
02:25PM  US STOCKS-Wall Street falls as Goldman, J&J weigh Reuters
02:11PM  Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition
01:55PM  After Johnson & Johnson Earnings, Buy These Pharma Stocks Zacks
01:52PM  Will Biotechs Feel Johnson & Johnson's Pain?
01:48PM  Johnson & Johnson Explores Options for Diabetes Care Unit
01:27PM  You Live By Goldman, You Die By Goldman: Dow Drops 150 Points as Earnings Fail to Thrill
12:59PM  Valuation Concerns at J&J Morningstar
12:53PM  US STOCKS-Wall St down as Goldman, J&J's results disappoint Reuters
12:16PM  Midday Report: Stocks See Red as Financials, Health Care Sectors Drag Markets Lower
12:01PM  Dow Falls On Goldman Miss; Netflix Disappoints; Dycom Breaks Out Investor's Business Daily
11:32AM  J&J first quarter revenue misses estimates; new forecast includes Actelion Reuters
11:30AM  US STOCKS-Weak Goldman, J&J results drag down Wall Street Reuters
11:19AM  Johnson & Johnson says pricing competition squeezed 1Q sales Associated Press
11:18AM  Johnson & Johnson: Help Me Actelion, You're My Only Hope
11:15AM  Watching Pullbacks for an Entry
11:04AM  The 4 Best Dividend Stocks in Pharmaceuticals Motley Fool
10:44AM  Goldman Sachs' Slide Leads Dow Lower; Bank of America Slips
10:41AM  Stocks Fall As 3 Big Dow Stocks Report; Which One's On Tap Next? Investor's Business Daily
10:24AM  Q1 Earnings Results, Theresa May Calls for New Snap Vote Zacks
10:20AM  J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down Zacks
10:13AM  [$$] J&J Lifts Forecast on Actelion Tie-Up The Wall Street Journal
10:03AM  US STOCKS-Wall St falls as Goldman, J&J results disappoint Reuters
09:35AM  Why Johnson & Johnson Raised Guidance After Missing Sales Estimates 24/7 Wall St.
09:27AM  Johnson & Johnson Posts Sluggish Sales, Boosts Guidance on Actelion Deal Motley Fool
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM